People
Factory-CRO Group, a leading global contract research organization, is pleased to announce Sapna Hornyak as its new president and CEO and the appointment of Nick Thornton to chairman of its board of directors.
Although the advent of cell and gene therapies is revolutionizing medicine, it is arguable that the therapies that have been approved to date in this area aren’t living up to expectations.
There are several lessons that companies and investors can learn from the collapse of Theranos, and one of the key takeaways is in the area of transparency.
Invitrocue Limited is pleased to provide its Appendix 4C cash flow statement for the quarter ended March 31, 2019 and to announce the appointment of Dr Sharifuddin Abdul Wahab as Global Insurance Advisor.
NOXXON Pharma N.V. announced the appointment of Dr. Maurizio PetitBon, member of the Supervisory Board since September 2016, as Chairman of NOXXON’s Board.
The industry was shaken up when Tokyo-based Eisai and its collaboration partner, Biogen, announced they were abandoning huge swaths of their Alzheimer’s program related to aducanumab in late March.
Despite continued slumps in sales of its hepatitis C medications, Gilead Sciences saw a robust first quarter, with earnings up nearly 28 percent. That was good news as new Chief Executive Officer Dan O’Day marked his first full quarter with the California-based company.
Curbing the opioid crisis will continue to be a key focus for the FDA. Ned Sharpless talked about new packaging rules that are expected to help stem the concerns about too many opioids on the streets.
The executives, convicted under the RICO Act, were found guilty of bribing prescribers and defrauding insurers in order to increase sales of Subsys, a powerful opioid pain killer intended for use with cancer patients.
The Society for Clinical Research Sites (SCRS) announced that Chris Hoyle, founder and executive director of Elite Research Network, has joined the organization’s Leadership Council.
PRESS RELEASES